Form 4: Fractyl Health Director Receives Stock Option Grant
Statement of Changes in Beneficial Ownership
Director Christopher Charles Thompson was granted 22,500 stock options as part of Fractyl Health's non-employee director compensation policy.
Summary
- Christopher Charles Thompson, a director at Fractyl Health, Inc. (GUTS), was granted 22,500 stock options.
- The options have an exercise price of $0.7318 per share.
- The grant date for these options is June 10, 2026.
- The options are set to expire on June 9, 2036.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial strategy.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- Minor dilution of existing shares upon the potential future exercise of these options.
Risks
- Vesting is contingent upon continued service on the board of directors through the vesting date.
Future Outlook
The options vest in a single installment on the earlier of the next annual meeting of stockholders or the first anniversary of the grant, provided the director remains in service.
Industry Context
StockSavvy.ai notes that equity grants for non-employee directors are standard corporate governance practice in the biotechnology sector to attract and retain board talent.
Comparison to Industry Standards
- The use of annual equity grants for board members is consistent with standard compensation practices for publicly traded life sciences companies.
- The vesting schedule tied to the next annual meeting or one-year anniversary is a common retention mechanism in the industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Grant of stock options pursuant to the non-employee director compensation policy. | 06/10/2026 | Standard alignment of director incentives with company performance. |
Stakeholder Impact
- Minimal impact on shareholders due to the standard nature of director equity compensation.
Next Steps
- Vesting of the 22,500 stock options on the earlier of the next annual meeting or June 10, 2027.
Key Dates
| Date | Description |
|---|---|
| 06/10/2026 | Date of the stock option grant transaction. |
| 06/11/2026 | Date the Form 4 was signed and filed. |
| 06/09/2036 | Expiration date of the granted stock options. |
Keywords
Fractyl Health, GUTS, Form 4, Director Compensation, Stock Options, Insider Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.